Ipamorelin: A Selective GH Secretagogue

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide, first described in 1998 as the first selective growth hormone (GH) secretagogue (Eur J Endocrinol). It does not introduce growth hormone directly. Instead, it signals the body's own pituitary gland to release it. Selectivity is the point: in that early pharmacology work, ipamorelin raised GH without the rises in cortisol and prolactin that some other secretagogues caused, and the original authors pointed to that clean profile as what made it a candidate worth developing.

How it works

Ipamorelin acts as a ghrelin mimetic, meaning it engages the same receptor pathway as ghrelin, the hormone best known for driving hunger that also has a role in growth hormone signaling. By binding this receptor in the pituitary, it triggers a pulse of growth hormone release. This is a mechanism-level description drawn from the foundational 1998 pharmacology research, which showed GH-releasing potency in cell, rat, and swine models comparable to the reference peptide GHRP-6, but without the adrenocorticotropic hormone and cortisol release those comparators produced.

Ipamorelin also acts on the gut, separate from its effect on the pituitary. A 2009 preclinical study in a rodent model of ileus (J Pharmacol Exp Ther) found that it accelerated colonic transit and, with repeated dosing, increased fecal output, food intake, and body weight gain after surgery, all through ghrelin-receptor activity in the gut rather than through GH release.

Human evidence: gut recovery after surgery

The human evidence is concentrated in one area: recovery of gut function after abdominal surgery. The most rigorous data comes from a 2014 phase 2 randomized, double-blind, placebo-controlled trial that tested intravenous ipamorelin for postoperative ileus, the temporary slowdown of the gut that can follow surgery (Int J Colorectal Dis). In that 114-patient proof-of-concept study, median time to a first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, a difference that did not reach statistical significance, and ipamorelin was well tolerated. A larger phase 2 dose-finding trial of 320 patients undergoing bowel resection (NCT01280344) was also completed, extending the same surgical-recovery question across multiple dose levels.

The popularized uses outrun the evidence

Ipamorelin is widely promoted for muscle, sleep, body composition, and longevity. Those uses are inferred from its mechanism: because growth hormone influences metabolism, tissue repair, and body composition, the interest is reasonable. But no completed human trial has tested ipamorelin for any of them. The published record runs to gastrointestinal recovery and the compound's core GH-releasing pharmacology, and nothing further.

Whether ipamorelin suits any individual is a question for a qualified physician, after reviewing health history, goals, and the state of the evidence. Anyone with a history of cancer, hormone-sensitive conditions, or significant endocrine issues in particular needs careful medical evaluation, because growth hormone pathways interact with many systems in the body. We do not provide dosing or administration guidance here, by design.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Ipamorelin is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.